Log in

NASDAQ:HARP - Harpoon Therapeutics Stock Price, Forecast & News

$15.01
-1.19 (-7.35 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$14.93
Now: $15.01
$16.23
50-Day Range
$13.29
MA: $14.73
$16.95
52-Week Range
$9.07
Now: $15.01
$21.47
Volume131,351 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees45
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.


Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) issued its quarterly earnings results on Monday, August, 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.14. The business had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.22 million. View Harpoon Therapeutics' Earnings History.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Harpoon Therapeutics.

What price target have analysts set for HARP?

7 Wall Street analysts have issued 12-month target prices for Harpoon Therapeutics' stock. Their forecasts range from $23.00 to $28.00. On average, they anticipate Harpoon Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 66.6% from the stock's current price. View Analyst Price Targets for Harpoon Therapeutics.

What is the consensus analysts' recommendation for Harpoon Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harpoon Therapeutics.

Has Harpoon Therapeutics been receiving favorable news coverage?

News stories about HARP stock have trended neutral on Sunday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Harpoon Therapeutics.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 329,000 shares, an increase of 32.1% from the January 15th total of 249,100 shares. Based on an average daily volume of 114,900 shares, the short-interest ratio is currently 2.9 days. Currently, 2.4% of the shares of the stock are short sold. View Harpoon Therapeutics' Current Options Chain.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), NVIDIA (NVDA), Precision BioSciences (DTIL), Gossamer Bio (GOSS), Advanced Micro Devices (AMD), Intel (INTC), Kaleido Biosciences (KLDO), Universal Display (OLED) and Tcr2 Therapeutics (TCRR).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the folowing people:
  • Dr. Luke B. Evnin, Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (0.50%), Renaissance Technologies LLC (0.45%), CIBC World Markets Inc. (0.12%), Bank of New York Mellon Corp (0.09%), Russell Investments Group Ltd. (0.09%) and Oxford Asset Management LLP (0.08%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View Institutional Ownership Trends for Harpoon Therapeutics.

Which institutional investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks and Patrick Baeuerle. View Insider Buying and Selling for Harpoon Therapeutics.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, CIBC World Markets Inc., Russell Investments Group Ltd., Oxford Asset Management LLP, State Street Corp, UBS Group AG, Barclays PLC and Bank of New York Mellon Corp. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon and Luke Evnin. View Insider Buying and Selling for Harpoon Therapeutics.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $15.01.


MarketBeat Community Rating for Harpoon Therapeutics (NASDAQ HARP)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote "Outperform" if you believe HARP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel